Biosimilars market report, by product types, application and, geography – analysis, share, trends, size, & forecast 2016 – 2025 – Research and Markets.
Research and Markets has announced the addition of the “Biosimilars Market Report, by Product Types, Application and, Geography – Analysis, Share, Trends, Size, & Forecast 2016 – 2025” report to their offering.
The market for biosimilars offers tremendous growth opportunities for the operating companies to record high revenue growth. Thus, large numbers of key companies such as Hospira, Inc., Teva Pharmaceutical, Amgen, Actavis, and others are in constant efforts to develop novel biosimilar and spending huge amount of their profits for research and development activities.
For instance, Hospira, Inc. increasing their research and development expenses on clinical trials to introduce novel biosimilars which would ultimately drive the market growth. Additionally, Amgen, Inc. have strong research pipeline (phase III molecule) for the biosimilar products such as ABP 501, ABP 980, and ABP 215.
Furthermore, demand for biosimilars is also expected to increase due to the rise in the incidence of diseases such as cancer, cardiovascular problem, and others. For these diseases, biosimilars have proven a promising option for the disease diagnosis and mitigation.
Other factors such as rising number of off-patented drugs, positive result of many biosimilar clinical trials, and others drive the market growth to a great extent. However, a strict regulatory framework for the biosimilar manufacturers to develop these products restricts companies to invest in this market, leading to hampering the market growth during the future period.
The global market for biosimilars is characterized by companies such as Sandoz Pharma, Stada Arzneimittel AG, Amgen, Hospira, Inc., Actavis, Cipla Ltd., Wockhardt Ltd., Biocon Ltd., and others.
Biosimilars for the pharmaceutical products such as insulin, human growth hormone, and blood products are considered as the high-interest market for these companies. Thereby, companies are increasingly investing to introduce these types of biosimilar products. For these, companies are increasingly investing in research and development activities to introduce novel biosimilar products.
To view the full press release, click here.
Filed Under: Drug Discovery